The Technical Analyst
BeyondSpring Inc [BYSI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BeyondSpring Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
8.53% $2.29
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 89.35 mill |
| EPS: | -0.710 |
| P/E: | -3.23 |
| Earnings Date: | Apr 23, 2024 |
| SharesOutstanding: | 39.02 mill |
| Avg Daily Volume: | 0.227 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.23 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.55x |
| Company: PE -3.23 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.466 (-120.34%) $-2.76 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.921 - 2.58 ( +/- 14.62%) |
| ATR Model: 14 days |
Forecast:
16:00 - $2.25
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.25
Forecast 2: 16:00 - $2.25
Forecast 3: 16:00 - $2.25
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.29 (8.53% ) |
| Volume | 0.112 mill |
| Avg. Vol. | 0.227 mill |
| % of Avg. Vol | 49.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BYSI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-03-25 07:00:00 - Press Release
Beyondspring Announces First Patient Dosed With Pembrolizumab, plinabulin plus Etoposide/platinum In A Phase 2 Investigator-initiated Study Of First-line Extensive-stage small-cell Lung Cancer
Florham park, n.j., march 25, 2024 (globe newswire) -- beyondspring inc. (nasdaq: bysi) (“beyondspring” or the “company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a phase 2 investigator-initiated trial (iit) with pembrolizumab, plinabulin, beyondspring's lead asset, plus etoposide/platinum (ep) for first-line (1l) extensive-stage small-cell lung cancer (es-sclc) [nct05745350].
2024-01-10 15:00:00 - Press Release
Beyondspring Receives Nasdaq Delinquency Notice Regarding Late Filing Of Its Form 6-k
New york, jan. 10, 2024 (globe newswire) -- beyondspring inc. (nasdaq: bysi) (“beyondspring” or the “company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on january 4, 2024, it received a foreign delinquency compliance plan alert letter (the “letter”) from the nasdaq stock market llc (“nasdaq”). in the letter, the staff of nasdaq notified the company that it is not in compliance with nasdaq listing rule 5250(c)(2), because it has not timely filed its form 6-k for the period ended june 30, 2023 (the “filing”).
2023-12-18 16:30:00 - Press Release
Beyondspring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
New york, dec. 18, 2023 (globe newswire) -- beyondspring inc. (nasdaq: bysi) (“beyondspring” or the “company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on december 14, 2023, it received a written notification from the nasdaq stock market llc (“nasdaq”) that the company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in nasdaq listing rule 5550(a)(2), because the closing bid price of the company's ordinary shares (the “ordinary shares”) was below $1...
2023-11-07 07:00:00 - Press Release
Beyondspring Presents Poster Highlighting Preclinical And Clinical Poc Immunomodulating Activity Of Plinabulin Inducing Dendritic Cell Maturation And Re-sensitization In Immunotherapy Refractory Tumors When Combined With Radiation And Pd-1/pd-l1 Inhibitors
New york, nov. 07, 2023 (globe newswire) -- beyondspring inc. (nasdaq: bysi) (“beyondspring” or the “company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced new data that translates preclinical proof-of-concept to clinical evidence of plinabulin's immunomodulating activity. beyondspring and md anderson presented the data at the society for immunotherapy of cancer's (sitc) 38th annual meeting on nov 4th in san diego, ca on an open-label, phase 1 basket study at the university of texas md anderson cancer center in cancer patients after progressing on pd-1, pd-l1 and/or ctla-4 antibodies (nct04902040) in six cancer types.
2023-10-23 07:45:00 - Press Release
Seed Therapeutics, A Beyondspring Subsidiary, Appoints Mr. Ko-yung Tung To The Board Of Directors
Former eisai board member, former world bank general counsel, and lecturer at harvard and yale law schools, brings five decades of experience in global health, law, governance, and international business former eisai board member, former world bank general counsel, and lecturer at harvard and yale law schools, brings five decades of experience in global health, law, governance, and international business
Latest News
2023-09-27 10:00:00 - GlobeNewsWire
BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced the presentation of a poster at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place on November 3 through 5 in San Diego, CA.
2023-09-07 08:00:00 - GlobeNewsWire
BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that management will present and participate in the R.W. Baird's 2023 Global Healthcare Conference, taking place on September 12 to 13, 2023 in New York City.
2023-05-18 08:30:00 - GlobeNewsWire
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that the Company and Memorial Sloan Kettering Cancer Center (MSK) will present a poster at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place on June 2 through 6 in Chicago, IL.
2022-12-15 13:40:59 - PennyStocks
Penny Stocks To Buy? 4 To Watch Before Next Week
2022-04-14 13:06:06 - Seeking Alpha
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript
BeyondSpring Inc. (NASDAQ:BYSI ) Q4 2022 Earnings Conference Call April 14, 2022 8:00 AM ET Company Participants Ashley Sierchio - LifeSci Advisors Lan Huang - Co-Founder, Chairman and CEO Ramon Mohanlal - EVP, Research & Development and Chief Medical Officer Elizabeth Czerepak - CFO Conference Call Participants Maurice Raycroft - Jefferies Joel Beatty - Robert W. Baird Joseph Pantginis - H.C.
2022-04-08 08:00:00 - GlobeNewsWire
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:00 am Eastern Time.
2022-01-12 05:43:50 - Benzinga
BeyondSpring Cuts On-Third Of Its Workforce
BeyondSpring Inc (NASDAQ: BYSI) plans to reduce its U.S. workforce by 35%, including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend the cash runway. The reorganization follows the FDA Complete Response Letter for plinabulin marketing application to prevent chemotherapy-induced neutropenia (CIN).
2021-12-30 10:43:22 - Zacks Investment Research
BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-12-30 09:23:04 - PennyStocks
Top Premarket Penny Stocks To Watch In The Stock Market Today
Premarket stocks to watch under $5 gaining steam in the stock market today. The post Top Premarket Penny Stocks To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-15 10:23:52 - Benzinga
BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia
BeyondSpring Inc (NASDAQ: BYSI) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Annual Meeting and Exposition. The comparison was made between cancer patients receiving plinabulin 40 mg (n=228) or not receiving plinabulin (n=172) and with all patients receiving myelosuppressive chemotherapy.